Development of EKZ-102, a CNS-Penetrant Small Molecule HDAC6 Inhibitor as a Potential First-in-class Disease Modifying Therapeutic for ALS
Time: 11:30 am
day: Conference Day Two Workshop A
Details:
- Eikonizo is developing highly selective, potent, orally bioavailable, CNS-penetrant, first-in-class small molecule HDAC6 inhibitors for neurodegeneration
- Development candidate, EKZ-102, is a potentially diseasemodifying therapeutic for both sporadic and familial ALS designed to correct broad proteostasis and intracellular transport defects to protect neurons and preserve function
- EKZ-102 IND-enabling studies are underway with planned clinical start in late 2025
